Ionis Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Ionis Pharmaceuticals şirketinin toplam hissedar öz sermayesi $662.5M ve toplam borcu $1.8B olup, bu da borç-öz sermaye oranını 275.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $3.1B ve $2.4B dir.

Anahtar bilgiler

275.7%

Borç/özkaynak oranı

US$1.83b

Borç

Faiz karşılama oranı	n/a
Nakit	US$2.49b
Eşitlik	US$662.47m
Toplam yükümlülükler	US$2.42b
Toplam varlıklar	US$3.08b

Son finansal sağlık güncellemeleri

Recent updates

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Oct 23

There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Aug 24

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

Aug 11

Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Jul 28

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

May 28

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

May 09

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Apr 14

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Mar 18

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Feb 23

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Dec 28

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Dec 07

A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Nov 16

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Aug 03

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

May 05

Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?

Jan 20

Ionis Pharmaceuticals Looks Good For The Long Term

Oct 19

Ionis plans for new manufacturing site in California to support pipeline

Oct 13

Ionis: 2 Drug Advancements With Potential Firsts

Aug 29

Ionis Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: IONS 'nin kısa vadeli varlıkları ( $2.7B ) kısa vadeli yükümlülüklerini ( $304.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: IONS şirketinin kısa vadeli varlıkları ( $2.7B ) uzun vadeli yükümlülüklerini ( $2.1B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: IONS şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: IONS şirketinin borç/öz sermaye oranı son 5 yılda 43.8% seviyesinden 275.7% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: IONS şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: IONS tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Ionis Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?

Recent updates

Independent Chairman of the Board notifies of intention to sell stock

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Astrazeneca and Ionis' Wainzua (Eplontersen) Recommends Approval by the Committee for Medicinal Products for Human Use in the European Union

Ionis Pharmaceuticals, Inc. Announces Zilganersen Granted U.S. FDA Fast Track Designation for People Living with Alexander Disease

Ionis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Ionis Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $500.25 million.

There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2024

Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Ionis Pharmaceuticals, Inc. Announces Positive Detailed Results from the HALOS Study of ION582 in People with Angelman Syndrome

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces olezarsen FCS New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed

Independent Director notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Presents Positive Results from OASIS-HAE and OASISplus Studies of Investigational Medicine Donidalorsen in Patients with Hereditary Angioedema

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Lead Independent Director exercised options to buy US$612k worth of stock.

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

Ionis Pharmaceuticals, Inc. Reaffirms Financial Guidance for the Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224

Ionis Pharmaceuticals, Inc. Announces Executive Changes

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS

Founder recently sold US$1.2m worth of stock

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Ionis and AstraZeneca's WAINUA

Insider notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Appoints Michael Yang as a Member of Board

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. Shares Positive Clinical Update from Ongoing Trial of Ion582 for Angelman Syndrome

Ionis Presents Positive Two-Year Results from the Phase 2 Open-Label Extension Study of Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Senior Strategic Advisor & Director notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces Positive Olezarsen Topline Results from Phase 3 Study in People with Facilitate Chylomicronemia Syndrome

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Ionis Completes Enrollment in Phase 3 Cardio-TTRansform Study in Patients with TTR-Mediated Amyloid Cardiomyopathy

Ionis Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Ionis Pharmaceuticals, Inc. Announces Positive Topline, 85-Week Data from the Phase 3 Neuro-Ttransform Study in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces New Data Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Medical Needs After Gene Therapy

Ionis Pharmaceuticals, Inc. Announces Positive Donidalorsen Late-Stage Clinical Progress in HAE

Founder notifies of intention to sell stock

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.2% to US$47.48

Full year 2022 earnings: EPS exceeds analyst expectations

Founder recently sold US$1.0m worth of stock

Ionis Pharmaceuticals, Inc. Announces GSK Has Advanced Bepirovirsen into Phase 3 Development

Ionis Receives FDA Fast Track Designation for Olezarsen in Patients with Familial Chylomicronemia Syndrome

Founder exercised options and sold US$990k worth of stock

Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?